Amneal Pharmaceuticals Recalls Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL)

News
Article

The company is recalling three lots of Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) due to potential N-Nitrosodimethylamine (NDMA) contamination.

Amneal Pharmaceuticals, Bridgewater, NJ, announced on April 15, 2020 that it was recalling three lots of Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL), packaged in 480 mL bottles and distributed by Gemini Laboratories, because of potential N-Nitrosodimethylamine (NDMA) contamination.

Nizatidine Oral Solution is used for the short-term treatment of ulcers and esophagitis and associated heartburn due to gastroesophageal reflux disease. NDMA is classified as a probable human carcinogen and is a known environmental contaminant found in water and foods.

The affected Nizatidine Oral Solution lots were distributed directly to wholesalers and then were distributed to retail pharmacies and consumers nationwide in the United States. The company has not received any reports of adverse effects. Adverse events may be reported to FDA through its MedWatch program.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes